ECSP14013236A - Polimorfos de inhibidores de cinasas - Google Patents

Polimorfos de inhibidores de cinasas

Info

Publication number
ECSP14013236A
ECSP14013236A ECSP14013236A ECSP14013236A EC SP14013236 A ECSP14013236 A EC SP14013236A EC SP14013236 A ECSP14013236 A EC SP14013236A EC SP14013236 A ECSP14013236 A EC SP14013236A
Authority
EC
Ecuador
Prior art keywords
polymorphes
kinase inhibitors
activity
mtor
chemical compounds
Prior art date
Application number
Other languages
English (en)
Inventor
Pingda Ren
Michael Martin
Original Assignee
Intellikine Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47669006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013236(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intellikine Llc filed Critical Intellikine Llc
Publication of ECSP14013236A publication Critical patent/ECSP14013236A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En el presente documento se describen polimorfos, hidratos y solvatos de compuestos químicos que modulan la actividad de cinasa, que incluyen actividad de mTOR y compuestos químicos, composiciones farmacéuticas y procedimientos de tratamiento de enfermedades y afecciones asociadas a actividad de cinasa, que incluyen actividad de mTOR.
ECSP14013236 2011-08-11 2014-03-11 Polimorfos de inhibidores de cinasas ECSP14013236A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161522624P 2011-08-11 2011-08-11

Publications (1)

Publication Number Publication Date
ECSP14013236A true ECSP14013236A (es) 2014-06-30

Family

ID=47669006

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013236 ECSP14013236A (es) 2011-08-11 2014-03-11 Polimorfos de inhibidores de cinasas

Country Status (24)

Country Link
US (1) US20150065524A1 (es)
EP (1) EP2741749A4 (es)
JP (1) JP2014521726A (es)
KR (1) KR20140079368A (es)
CN (1) CN103957918A (es)
AU (1) AU2012294202B2 (es)
BR (1) BR112014003214A2 (es)
CA (1) CA2844742A1 (es)
CL (1) CL2014000343A1 (es)
CO (1) CO6960542A2 (es)
CR (1) CR20140082A (es)
DO (1) DOP2014000027A (es)
EA (1) EA027970B1 (es)
EC (1) ECSP14013236A (es)
HK (1) HK1199203A1 (es)
IL (1) IL230850A0 (es)
MX (1) MX2014001662A (es)
MY (1) MY186267A (es)
PE (1) PE20141358A1 (es)
RU (1) RU2636588C2 (es)
SG (2) SG10201606288TA (es)
TN (1) TN2014000063A1 (es)
WO (1) WO2013023184A1 (es)
ZA (1) ZA201401211B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2368941T3 (es) 2003-01-06 2011-11-23 Angiochem Inc. Angiopep-1, compuestos relacionados y utilizaciones correspondientes.
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2346896A4 (en) 2008-10-15 2014-06-25 Angiochem Inc CONJUGATES OF ETOPOSIDE AND DOXORUBICIN FOR THE ADMINISTRATION OF MEDICAMENTS
RU2011118056A (ru) 2008-10-15 2012-11-27 Ангиокем Инк. Конъюгаты агонистов glp-1 и их применение
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
MX2011006685A (es) 2008-12-17 2011-09-27 Angiochem Inc Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
CN102510759A (zh) 2009-04-20 2012-06-20 安吉奥开米公司 利用与血管肽-2类似物结合的抗癌剂治疗卵巢癌
JP5932642B2 (ja) 2009-07-02 2016-06-08 アンジオケム インコーポレーテッド 多量体ペプチドコンジュゲートおよびその使用
CN106994126A (zh) * 2011-11-08 2017-08-01 因特利凯有限责任公司 使用多种药剂的治疗方案
CN104250250A (zh) * 2013-06-25 2014-12-31 苏州科捷生物医药有限公司 4-芳香胺基嘧啶类化合物及其抗肿瘤用途
KR20160084438A (ko) 2013-11-13 2016-07-13 노파르티스 아게 면역 반응을 강화하기 위한 mTOR 억제제
CA3225453A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
AU2015292755B2 (en) 2014-07-21 2020-11-12 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
EP3174546B1 (en) 2014-07-31 2019-10-30 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
US10851149B2 (en) 2014-08-14 2020-12-01 The Trustees Of The University Of Pennsylvania Treatment of cancer using GFR α-4 chimeric antigen receptor
MY189028A (en) 2014-08-19 2022-01-20 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
AU2015317608B2 (en) 2014-09-17 2021-03-11 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CN114107424A (zh) 2014-10-08 2022-03-01 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
JP7114457B2 (ja) 2015-04-17 2022-08-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
ES2636646B1 (es) * 2016-04-05 2018-08-03 Universidade De Santiago De Compostela NUEVOS VEHÍCULOS PARA LA TRANSFECCIÓN DE miRNAs
CN116769050A (zh) 2016-07-20 2023-09-19 犹他大学研究基金会 Cd229 car t细胞及其使用方法
CN110225927B (zh) 2016-10-07 2024-01-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
BR112019010511A2 (pt) 2016-11-23 2019-09-17 Bayer Ag derivados de heterociclo bicíclico fundido como pesticidas
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
JP7296401B2 (ja) * 2018-01-09 2023-06-22 ハルシオン ラブス プライベート リミテッド クリサボロールおよびその中間体を調製するためのプロセス
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
BR112013017670B1 (pt) * 2011-01-10 2022-07-19 Infinity Pharmaceuticals, Inc Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas

Also Published As

Publication number Publication date
ZA201401211B (en) 2015-12-23
BR112014003214A2 (pt) 2017-03-14
EP2741749A4 (en) 2015-04-15
MY186267A (en) 2021-07-01
WO2013023184A1 (en) 2013-02-14
AU2012294202A1 (en) 2014-03-06
CA2844742A1 (en) 2013-02-14
JP2014521726A (ja) 2014-08-28
DOP2014000027A (es) 2014-07-15
CN103957918A (zh) 2014-07-30
CR20140082A (es) 2014-06-03
SG10201606288TA (en) 2016-09-29
EP2741749A1 (en) 2014-06-18
RU2014109023A (ru) 2015-09-20
MX2014001662A (es) 2014-08-26
RU2636588C2 (ru) 2017-11-24
NZ622208A (en) 2016-04-29
PE20141358A1 (es) 2014-10-12
IL230850A0 (en) 2014-03-31
HK1199203A1 (en) 2015-06-26
US20150065524A1 (en) 2015-03-05
KR20140079368A (ko) 2014-06-26
CL2014000343A1 (es) 2014-10-17
CO6960542A2 (es) 2014-05-30
TN2014000063A1 (en) 2015-07-01
EA201490446A1 (ru) 2014-05-30
EA027970B1 (ru) 2017-09-29
AU2012294202B2 (en) 2017-02-23
SG2014009492A (en) 2014-09-26

Similar Documents

Publication Publication Date Title
ECSP14013236A (es) Polimorfos de inhibidores de cinasas
PH12018500960A1 (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
CR20120659A (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer
CU20160185A7 (es) Compuestos de heteroarilo para la inhibición de cinasa
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
CL2015000177A1 (es) Composición para el tratamiento de la hiperlipidemia que comprende un derivado de oxintomodulina
CR20150217A (es) Inhibidores de histona demetilasas
UY34401A (es) Métodos para el tratamiento de hcv
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
UY34402A (es) Métodos para el tratamiento de hcv
CL2015002027A1 (es) Compuestos quimicos
CR20160321A (es) Modulares de tetrahidropiridopirazinas de gpr6
CR20110440A (es) Compuestos de piridazinona
UY35513A (es) Inhibidores de la phd de 6-(5-hidroxi-1hpirazol-1-il)nicotinamida
CR20140024A (es) Compuestos inhibidores de metaloenzimas
DOP2012000263A (es) Compuestos quimicos
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
MX355728B (es) Inhibidores de cinasas.
DOP2012000238A (es) Compuestos de para la inhibición de inmunoproteasomas
CR20130539A (es) Triazolopiridinas
CL2014002661A1 (es) Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
MY187423A (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazine derivatives as modulators of gpr139